LOS ANGELES, Oct 18 (Reuters) - Gilead Sciences Inc posted a third-quarter profit that topped Wall Street targets on Thursday, driven by drugs that fight the virus that causes AIDS, reversing a year-ago loss on acquisition-related costs.Gilead said it now expects 2007 product revenue to land at the high end of its existing forecast range of $3.6 billion to $3.7 billion.
